BioMarin Pharmaceutical Inc (BMRN): Shareholders' Equity
$6.09B
As of 2025-12-31
$6.32B
As of 2026-06-30
+9.8%
3-year compound annual growth
+8.2%
5-year compound annual growth
+9.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.09B | +7.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $5.66B | +14.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $4.95B | +7.6% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $4.60B | +7.9% | 2025-02-24, Balance as of period end |
| 2021-12-31 | $4.27B | +4.0% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $4.10B | +31.3% | 2023-02-27, Balance as of period end |
| 2019-12-31 | $3.12B | +5.2% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $2.97B | +5.7% | 2021-02-26, Balance as of period end |
| 2017-12-31 | $2.81B | +1.5% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $2.77B | +15.2% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $2.40B | +57.1% | 2018-02-26, Balance as of period end |
| 2014-12-31 | $1.53B | +13.9% | 2017-02-27, Balance as of period end |
| 2013-12-31 | $1.34B | +32.0% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $1.02B | +31.4% | 2015-03-02, Balance as of period end |
| 2011-12-31 | $773.05M | +7.8% | 2014-02-26, Balance as of period end |
| 2010-12-31 | $717.26M | +122.6% | 2013-02-26, Balance as of period end |
| 2009-12-31 | $322.19M | +16.4% | 2012-02-22, Balance as of period end |
| 2008-12-31 | $276.68M | n/a | 2011-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $6.09B | +7.6% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $7.10B | +10.1% |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | -$70.79M | n/m |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $789.18M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.94B | -32.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $4.32B | +5.5% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $9.71B | -6.1% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $6.55B | +7.4% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $1.14B | -25.3% |
Compare BMRN, UTHR, AMRX, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗